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Although combination antiretroviral therapy can dramatically reduce the circulating viral load in those
infected with HIV, replication-competent virus persists. To eliminate the need for indefinite treatment, there
is growing interest in creating a functional HIV-resistant immune system through the use of gene-modified
hematopoietic stem cells (HSCs). Proof of concept for this approach has been provided in the instance of
an HIV-infected adult transplanted with allogeneic stem cells from a donor lacking the HIV coreceptor,
CCR5. Here, we review this and other strategies for HSC-based gene therapy for HIV disease.Background
HIV infection of CD4+ T cells leads to their death through mech-
anisms that are both direct (e.g., cytotoxicity) and indirect (e.g.,
activation-induced cell death). After years of heightened T cell
turnover, the capacity of the immune system to maintain normal
homeostasis is depleted and patients progress to advanced
immunodeficiency. The well-described morbidity and mortality
associated with untreated HIV infection is readily attributed to
failed immunity, with deficits in most hematopoietic lineages
causally associated with disease (McCune, 2001). Effective
suppression of HIV replication using combination antiretroviral
therapy essentially reverses the process of immune depletion
and often results in partial restoration of immune function,
improved health, and prolonged life.
Although antiretroviral therapy for HIV disease is an unques-
tioned success, it does have a number of limitations. First,
therapy does not fully restore health. Chronic inflammation
and immune dysfunction often persist indefinitely during
treatment, and these factors have been associated with
increased risk of non-AIDS morbidity and mortality (Deeks,
2011; Kuller et al., 2008). Second, antiretroviral therapy may
not be fully suppressive. There is emerging evidence that
cryptic virus replication persists within dispersed hematolym-
phoid organs (Yukl et al., 2010), with potentially significant
effects on T cell and myeloid cell homeostasis and function.
Third, combination therapy requires daily adherence to regi-
mens that often have side effects and complex drug-drug
interactions, and many individuals are unable to adhere to
such regimens indefinitely. Finally, resource limitations deny
the prospect of life-long therapy to many individuals who
need it most. Even with the massive global investment in HIV
care, access to these drugs will remain incomplete and the
epidemic will continue to spread.Given the well-recognized limitations of current therapeutic
approaches, there is growing interest in developing potentially
curative approaches. An ideal therapeutic cure would be one
that is safe, scalable, administered for a limited period of time,
and prevents infection of all susceptible cells, including cells in
tissues with limited bioavailability for antiretroviral drugs. To
reach this goal, it has been suggested (Baltimore, 1988; Gilboa
and Smith, 1994; Yu et al., 1994) that long-lived, self-renewing,
multilineage hematopoietic stem cells (HSCs) could be modified
such that both they and their progeny can resist HIV infection.
After introduction of these modified HSCs, the host could be
repopulated with an HIV-resistant hematopoietic system,
including CD4+ T cells and myeloid targets. If such a system
can be created, a lifelong cure will have been achieved.
To realize the goal of HSC-based gene therapy for HIV
disease, the following steps must be taken (Figure 1): HSCs
must be identified and purified (and/or expanded) in numbers
sufficient to provide a benefit in both adults and children;
methods must be devised to efficiently and stably introduce
novel gene functions into HSCs; the selected gene functions
must be shown to confer HIV resistance in progeny T cells and
myeloid cells; the gene-modified cells must be introduced into
the patient safely and efficiently; and clinical trials must be de-
signed to convincingly demonstrate efficacy. This review will
address each of these steps in turn and conclude with additional
thoughts about the worldwide dissemination and implementa-
tion of curative therapies for HIV.
Identification and Expansion of HSCS
Characterization of HSCs
A critical obstacle confronting the identification of human HSCs
was the lack of suitable assays available to test the multilineage
potential of candidate cells. The gold standardmethod to identifyCell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc. 137
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Figure 1. Intracellular Immunization with Gene-Modified Hematopoietic Stem Cells
Long-lived, self-renewing, multilineage hematopoietic stem cells (HSCs) could be modified such that they and their progeny resist HIV infection. The host
could thereafter be repopulated with a hematopoietic system (including CD4+ T and myeloid targets for HIV) that is resistant to the replication and spread
of HIV.
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can be shown to repopulate and reconstitute the entire hemato-
poietic system after myeloablative and otherwise lethal condi-
tioning. Ethical concerns obviously make this impossible to
test in humans. A significant advance to this field was provided
by the development of mouse models allowing the engraftment
and multilineage differentiation of human hematopoietic progen-
itor cells (Bhatia et al., 1998; Guenechea et al., 2001; Kaneshima
et al., 1990; Lapidot et al., 1992; Larochelle et al., 1996; McCune
et al., 1988, 1991; Namikawa et al., 1990). A critical limitation of
this approach is the inability to test the effect of the conditioning
regimens on engraftment and to evaluate the long-term genera-
tion of all lineages. Accordingly, large animal models (e.g.,
monkeys and dogs) were used to study HSC biology and trans-
plantation, and studies in the early 1990s demonstrated that
marrow cells can be enriched for subpopulations that possess
long-term repopulating capabilities (Berenson et al., 1988).
These studies used the marker CD34, which is still used today
if one wishes to perform ‘‘stem cell’’ enrichment or selection in
patients or T cell depletion. Although there are many other
markers [(e.g., Rholow cells identified by functional assays
(McKenzie et al., 2007) or so-called ‘‘side populations’’ (Goodell
et al., 1997)], such methods have not advanced into routine
clinical use for HSC selection or transplantation. Even if more
purified populations of stem cells can be obtained with novel
markers, the number of such cells that can be routinely obtained
may be insufficient to support rapid engraftment and expansion
in vivo.
At present, it is the general consensus that ‘‘true’’ self-renew-
ing human HSCs are found within a CD34+ population and that138 Cell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc.engraftment of a suitably conditioned host with a sufficient
number of such cells will result in long-term multilineage hema-
topoiesis. To obtain the requisite number of purified cells,
sophisticated methods for clinical grade, high-speed cell sorting
have been developed. Once this technology is refined and
approaches are developed to expand such cells ex vivo, it is
likely that defined hematopoietic stem and/or progenitor cell
populations can be targeted for genetic modification and used
to treat nonfatal conditions such as treated HIV disease.
Expansion of HSCs
Over the past 20 years, numerous efforts have been made to
expand HSCs in vitro so they will be more readily accessible
for use in vivo. Initial studies relied on hematopoietic growth
factors such as G-CSF, SCF, Flt3, IL-3, IL-6, and thrombopoietin
(McNiece et al., 2000), but these approaches failed to result in
substantial HSC expansion. Since then, a number of other
factors have been studied: HOXB4 and NUP98 (Gurevich et al.,
2004; Krosl et al., 2003; Sauvageau et al., 2004), Notch ligands
(Delaney et al., 2010), WNT (Reya et al., 2003), pleiotrophin (Him-
burg et al., 2010), and prostaglandin (North et al., 2007, 2009).
The use of angiopoietin-like 5 and insulin-like growth factor has
also been reported to provide some benefit for HSC expansion
in vitro (Zhang et al., 2008). Probably themost successful expan-
sion reagent to be identified has been the purine derivative Stem-
Regenin 1 (SR1), which promotes the ex vivo expansion of
CD34+ cells (Boitano et al., 2010), and is reportedly responsible
for a 50-fold increase in the number of CD34+ cells obtained in
culture and a 17-fold increase in the number of cells able to
engraft in NSG mice. The ability of these expanded HSCs to
engraft in humans is unknown.
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Figure 2. Basic Design of an SIN Configured Vector
(A) A traditional retroviral vector with two functional long terminal repeats
(LTRs) that contain strong enhancer and promoter elements. Integration of this
vector can lead to activation of nearby proto-oncogenes and thus leukemia.
(B) A self-inactivating (SIN) lentivirus vector design. The 30 LTR is modified
(delta) so it does not contain any transcriptional control elements. Thus, upon
transduction and integration into the genome, both 50 and 30 LTRs are
defective and will not contain any functional promoter or enhancer elements.
A weaker internal promoter (e.g., PGK) can then be inserted to drive expres-
sion of the transgene and thus decrease the risk of activating any nearby proto-
oncogenes.
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optimize the procedures for expanding multipotential HSCs
(Watts et al., 2010). Ongoing studies of Notch pathway modula-
tion using Delta-1 and SR1 are being pursued in a clinical setting,
primarily in allogeneic transplantation studies. These studies are
unlikely to determine true expansion of long-term repopulating
cells, but rather will evaluate the contribution to short-term
reconstitution. Although progress in identifying a safe and effec-
tive combination regimen for expanding HSCs has been limited,
there is intense interest in this area in both industry and
academia. It is expected that over the next several years an
approach to readily harvest HSCs from humans and expand
them ex vivo will be available.
Expansion of HSCs ex vivo may be particularly important for
HIV disease. For reasons that have yet to be fully defined but
that likely include HIV-mediated effects on important hemato-
lymphoid microenvironments, the number of hematopoietic
progenitor cells from HIV-infected patients to support immune
reconstitution may be diminished (Jenkins et al., 1998; McCune,
2001). Recent work by Appay and colleagues has also demon-
strated that CD34+ progenitor cells obtained from the peripheral
blood of such patients have reduced capacity to generate
mature T cells (Sauce et al., 2011). This effect of HIV on stem
cell function is comparable to that observed in advanced aging
and appears to be due, at least in part, to the indirect effects
of chronic inflammation.
Introduction of De Novo Gene Functions into HSCs
Assuming that a sufficient number of the appropriate HSC pop-
ulation can be obtained, it will be necessary to findways to stably
and efficiently introduce novel gene functions into such cells.
Two general approaches have been taken to achieve this end:
the use of integrating vector systems that permit the introduction
of anti-HIV genes into the genome of HSCs and nonintegrating
vector systems that introduce gene-modifying enzymes to effect
gene disruptions or homologous recombination.
Integrating Vector Systems
Much progress has been made in optimizing ex vivo transduc-
tion, and there are a number of vector systems available that
allow for efficient and stable gene delivery to HSCs. The intro-
duction of multiple hematopoietic cytokines and the RetroNectin
fragment (a recombinant human fibronectin fragment) have
successfully facilitated substantial improvements in the genetic
manipulation of HSCs (Hanenberg et al., 1996; Kiem et al.,
1998). In addition, the identification of appropriate viral pseudo-
types (e.g., GALV and RD114) has improved gene transfer
efficiencies. These vectors may also allow improved HSC main-
tenance (Horn et al., 2002; Kiem et al., 1998; Neff et al., 2004;
von Kalle et al., 1994). Recent protocols have focused on the
use of safety-modified, HIV-derived lentivirus vectors (Naldini
et al., 1996; Zufferey et al., 1997, 1998), an approach that
allows the generation of high-titer vectors and efficient gene
transfer to hematopoietic stem/progenitor cells. Other systems
have also been evaluated, such as foamy virus vectors and
different VSV-G pseudotypes (Kiem et al., 2007; Trobridge
et al., 2010).
Because the vector systems can be associated with genotox-
icity, and hence a risk of malignancy (Baum et al., 2011; Fischer
et al., 2010), the main focus of optimization for integrating vectorsystems has switched to safety. Unless gene knockouts or
knockins are performed, integrating vectors will be required to
obtain lifelong expression of the anti-HIV constructs. Given
that most HIV-infected adults have a good prognosis (assuming
they have access to effective therapy), there will be limited
interest in any vector system that has an appreciable risk of
malignant transformation. Thus, gamma retroviral vectors are
unlikely to be considered in large-scale clinical trials because
these have been associated with a high risk of leukemia in prior
transplant protocols. Fortunately, improved vector systems have
been developed and evaluated, and the currently used lentivirus
and foamy virus vectors appear to have limited risk for malignant
transformation (Hacein-Bey-Abina et al., 2008; Modlich et al.,
2009; Zhou et al., 2010). The self-inactivating (SIN) lentivirus
and foamy virus vector systems are capable of integration but
have a nonfunctioning long terminal repeat (LTR) in the inte-
grated provirus and rely on a weaker internal promoter element
for expression of the transgene (Figure 2). The removal of the
strong LTR promoter reduces the potential for insertional activa-
tion of nearby genes (Zufferey et al., 1998). In addition to the SIN
configuration, lentivirus and foamy virus vectors have a more
favorable integration site pattern compared with gamma retro-
viral vectors.
Nonintegrating Vector Systems or Transfection
Analternative gene transfer approach is to utilize viral vectors that
have been modified so they are unable to integrate into the host
genome (Ya´n˜ez-Mun˜oz et al., 2006). A significant advantage of
nonintegrating vector systems is that they circumvent the risk
of insertional mutagenesis and resultant malignancy. This can
be done quite efficiently using integrase-deficient lentivirus
vectors or adenovirus vectors (Gabriel et al., 2011; Holt et al.,
2010; Lombardo et al., 2011). As discussed below,Cell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc. 139
Figure 3. Approaches to Modifying Hematopoietic Stem Cells for HIV Resistance
Both transient and permanent CCR5 suppression can be achieved using nonintegrating delivery vectors. By contrast, durable expression of HIV resistance
elements will likely require integrating delivery vectors. While concerns remain about the possibility of insertional mutagenesis (as observed previously with
gamma-retrovirus vectors), the safety of integrating approaches has improved greatly in recent years with the development of lentivirus and foamy virus vectors.
Heavier arrows depict desired outcomes; lighter arrows depict less desirable outcomes.
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delivery of zinc finger nucleases or other DNA-editing enzymes
that can induce permanent knockout of specific genetic loci
after only transient expression. However, and as with all new
reagents, more safety studies are needed to confirm the lack of
off-target effects and genotoxicity (Mussolino and Cathomen,
2011).
Selection of Gene Functions to Confer Resistance to HIV
Approaches aimed at modifying HSCs to treat HIV disease can
be grouped into two main themes: targeted disruption of cellular
genes involved in HIV entry, such as the CCR5 coreceptor, and
the introduction of genes that interfere with HIV replication,
such as fusion inhibitors or host restriction factors (Figure 3).
Targeted Gene Knockdown or Knockout
CCR5 is a G protein-coupled chemokine receptor that also func-
tions as a critical coreceptor during entry of ‘‘R5’’ strains of HIV.
Given redundancies in the immune system, CCR5 is not critical
for normal immune function and certain healthy individuals carry
a mutation in the CCR5 gene that prevents expression of a
functional protein. This CCR5-D32 (D32) mutation is present in140 Cell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc.5%–14% of individuals of European descent but is rare in
persons of African or Asian descent. HIV disease progresses
more slowly in individuals with a single copy of the D32 mutation
(de RodaHusman et al., 1997), while homozygous individuals are
largely resistant to HIV infection (Liu et al., 1996; Samson et al.,
1996). Thus, CCR5 has been an attractive antiviral target, and
the successful development ofmaraviroc, an allosteric, noncom-
petitive inhibitor of CCR5, has proven that inhibition of this
receptor effectively inhibits HIV replication in a safe and durable
manner (Gilliam et al., 2011).
Because of its proven clinical importance, CCR5 has been
intensely studied as a target for stem cell therapies. Several
approaches have been taken to inhibit functional expression of
CCR5, including the introduction of siRNA (Kim et al., 2010;
Shimizu et al., 2010), ribozymes (DiGiusto et al., 2010; Feng
et al., 2000), trans-dominant mutant forms of CCR5 (Luis Abad
et al., 2003), and single chain intracellular antibodies (Stein-
berger et al., 2000; Swan et al., 2006).
The potential efficacy of permanent CCR5 elimination was
dramatically illustrated by the so-called ‘‘Berlin patient,’’ the
only documented example of an apparent cure of HIV infection
Figure 4. The Replicative Cycle of HIV
Two major strains of HIV-1 (R5 and X4) bind to
target cells by concerted interactions between the
envelope protein (Gp120) and CD4, and the che-
mokine coreceptors, CCR5 and CXCR4, respec-
tively, leading to a fusion event with the plasma
membrane that allows entry of the virion capsid
into the cytoplasm. Reverse transcription of viral
genomic RNA forms a series of replicative inter-
mediates that may ultimately integrate into the
host cell genome. Transcription and generation of
spliced and unspliced forms of the viral RNA
allows movement and packaging of the diploid
viral genome in the cytoplasm, a step enabled in
part by HIV-1 protease. Budding and release of
new viral progeny for repeated rounds of infection
is then facilitated by virally encoded release and
infectivity factors. Each of these steps can be
(or might be) disabled by specific drug and/or
gene therapy.
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tive patient with acute myeloid leukemia received an allogeneic
stem cell transplantation using cells from a donor homozygous
for the CCR5-D32 mutation. The patient efficiently engrafted
with CCR5 null cells and, as of this report 4 years later, remains
free of readily detectable circulating virus, even in the absence of
antiretroviral therapy (Allers et al., 2011). Unfortunately, alloge-
neic stem cell transplantation has significant associated morbid-
ities, limiting the widespread application of this approach
beyond patients with AIDS-associated malignancies. Further-
more, because CCR5/ stem cell donors are rare (particularly
among non-European ethnic groups) and must still be HLA-
matched with prospective HCST recipients, fewer than 1% of
AIDS patients would likely be eligible for this treatment (Hu¨tter
and Thiel, 2011). Thus, there is a critical need for a strategy to
create autologousCCR5/ stem cells and bypass each of these
problems.
The recent emergence of DNA editing proteins, including zinc
finger nucleases (Urnov et al., 2005), TAL effector nucleases
(Bogdanove and Voytas, 2011), and homing endonucleases
(Stoddard, 2011), has created the possibility that any genetic
locus can be specifically and permanently inactivated. This
approach can be applied to CCR5 in any cell type, including
a patient’s own HSCs. Initial studies used zinc finger nucleases
to disrupt CCR5 in primary human T cells (Perez et al., 2008).
In subsequent work, zinc fingers were used to disrupt CCR5 in
human HSCs, which were then tested in a humanized mouse
model of HIV infection (Holt et al., 2010). Disruption occurred in
17% of CCR5 alleles, resulting in HSCs with either heterozygous
or homozygous disruptions. The modified HSCs were able to
support multilineage hematopoiesis in the mice. After subse-
quent HIV challenge, the CCR5-disrupted progeny cells had
a selective advantage over the unmodified cells. Compared
with control animals, those receiving modified cells had lower
HIV loads and higher numbers of human cells. Based on these
promising results, clinical trials of zinc finger nucleases targeting
CCR5 in peripheral T cells are currently underway.
A potential concern of CCR5-directed therapies is that they
will drive selection of so-called ‘‘X4’’ viruses with tropism for
CXCR4, the other chemokine coreceptor utilized by HIV for
binding and entry into target cells. Although there has been
interest in simultaneously disrupting CXCR4 and CCR5,CXCR4 is widely expressed on many cell types throughout the
body and is critical for multiple physiologic processes, including
B cell, cardiovascular, and cerebellar development. Therefore,
CXCR4 may not be a suitable target for disruption in pluripotent
stem cells. By contrast, CXCR4 null mice have normal T cell
development (Nagasawa et al., 1996) and it may be possible to
successfully knock out CXCR4 in T-lineage restricted progenitor
cells. An initial study of zinc-finger-mediated disruption of
CXCR4 in a humanized mouse model of HIV infection showed
that this approach was well tolerated and provided resistance
to CXCR4-tropic virus (Wilen et al., 2011). Nevertheless, the
safety of CXCR4 disruption in humans remains a major concern.
Introduction of Genes that Interfere with HIV Infection
and Replication
An alternative strategy of HSC modification for HIV therapy
involves inserting new genetic elements that can inhibit critical
processes such as viral entry or replication (see Figure 4 and
Table 1). For instance, a gp41-derived peptide (C46) that is
structurally similar to the FDA-approved fusion inhibitor enfuvir-
tide can effectively inhibit HIV entry. An initial clinical trial of
C46-expressing, modified autologous T cells in ten patients
showed that the therapy was well tolerated (van Lunzen et al.,
2007). The addition of C46 into HSCs was also evaluated in
a macaque model of HIV infection (Trobridge et al., 2009);
marking efficiencies were 4%–7% in peripheral T cells, and the
modified T cells were protected from subsequent HIV challenge.
Of note, resistance to enfuvirtide occurs rapidly when it is used in
the absence of a fully suppressive antiretroviral regimen, raising
the possibility that C46-based HSC therapy might also be asso-
ciated with the development of viral resistance. However, the
genetic barrier for developing C46 resistance may be higher
than for enfuvirtide resistance. Resolution of this issue will ulti-
mately require experimental evaluation in vivo.
Exogenous elements can also be used to interfere with other
essential viral processes. In stem cells, the key HIV regulatory
protein Rev has been targeted using dominant mutant or trans-
dominant forms of Rev (Bonyhadi et al., 1997; Kang et al.,
2002; Podsakoff et al., 2005; Su et al., 1997). HIV Tat and its over-
lapping genes have also been targeted in stem cells using
hammerhead ribozymes, catalytically active RNA structures
that target critical gene regions (Amado et al., 2004; Mitsuyasu
et al., 2009). TAR decoys have been used to inhibit viralCell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc. 141
Table 1. Pharmacologic and Genetic Strategies to Inhibit HIV In Vivo
Mechanism Drug Treatment Gene Therapy/Gene Disruption
Gp120 binding inhibitors none
Coreceptor binding inhibitors maraviroc CCR5 KO, CXCR4 KO
Fusion inhibitors enfuvirtide C46
Reverse transcriptase Inhibitors abacavir, didanosine, emtricitabine,
lamivudine, stavudine, tenofovir, zidovudine,
efavirenz, etravirine, nevirapine, rilpivirine
Integrase inhibitors raltegravir, dolutegravir
Genome disruption evolved recombinases, endonucleases
Gene expression inhibitors TAR decoys, anti-Tat ribozymes, siRNA, shRNA
RNA export inhibitors trans-dominant, Rev (RevM10)
Protease inhibitors atazanavir, amprenavir, darunavir, indinavir,
lopinavir/ritonavir, nelfinavir, saquinavir, tipranavir
Viral release or infectivity inhibitors TRIM5a, APOBECs, tetherin
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transactivator Tat (Banerjea et al., 2004). Both shRNA and siRNA
have been used to suppress expression of many HIV genes
(Rossi et al., 2007), although their transient effects may limit their
application in stem cells. Finally, the integrated viral DNA itself
has been directly targeted using evolved recombinases (Sarkar
et al., 2007) or homing endonucleases (Aubert et al., 2011),
and introduction of genes encoding such proteins could poten-
tially protect stem cells from viral infection and replication.
Unlike their human homologs, certain primate host restriction
factors, such as TRIM5a, APOBEC 3F and 3G, and tetherin, can
prevent HIV infection of cells and represent other potential candi-
dates for gene therapy. The anti-HIV effect of the primate mole-
cules often results from sequence variation compared to their
human homologs, making immunogenicity of the transgene
a potential limitation. In humanized mouse models, both
a human-rhesus chimeric TRIM5a (Anderson and Akkina, 2008)
and a human TRIM-cyclophilin A fusion (Neagu et al., 2009) were
well tolerated and protected cells fromHIV challenge, supporting
the promise of this approach.
Despite these encouraging results, the addition of exogenous
anti-HIV genetic elements into HSCs raises concerns. Insertions
of genes with their own promoters may generate risks from long-
term expression or insertional activation of nearby genes
(Burnett and Rossi, 2009; Li et al., 2005; Tiemann and Rossi,
2009). The expressed proteins may also be immunogenic in
the recipient, limiting the expansion or lifespan of modified cells.
By contrast, permanent disruption of CCR5 should be possible
using nonintegrating delivery methods; thus, this strategy is
likely to be the safest and most appealing strategy for clinical
settings. Nevertheless, in preclinical studies, combinations of
CCR5 knockdowns and other pathways that interfere with HIV
entry or replication should be pursued to identify the most effec-
tive approach.
Will Combination Therapy Be Needed?
Once HIV disease has reached the chronic phase, the set of viral
quasispecies within an infected individual is very diverse. In addi-
tion, variants that are naturally resistant to any given antiviral
agent may pre-exist in that population, which explains why
potent antiretroviral drugs often have only a transient effect on
HIV replication when given asmonotherapy. Based on the exten-142 Cell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc.sive experience with standard small-molecule antiretroviral
drugs, the ideal stem-cell-based intervention would require the
virus to develop multiple mutations to become resistant. For
example, a combination of two or more antiviral genes applied
simultaneously could provide a sufficient genetic barrier to
prevent the emergence of resistance. Efforts are already
underway to develop such combination approaches. One inter-
esting recent approach used a combination of a tat/rev shRNA,
a TAR decoy, and a CCR5-targeting ribozyme to modify
CD34+ stem cells in patients undergoing transplantation for
HIV-associated lymphoma (DiGiusto et al., 2010). While no
clinical benefit was observed given the low frequency of modi-
fied cells in this study (<0.2% of circulating PBMC), the proce-
dure was well tolerated and modified cells persisted for at least
24months. Improved approaches providing a higher percentage
of gene-modified cells should provide durable effects and will
also allow the determination of the minimal marking efficiency
required for clinical benefit and the relative benefits of various
therapeutic gene combinations.
Another issue distinguishing gene therapy from standard anti-
retroviral therapy pertains to the possible role of partial viral
suppression during the early phases of treatment. If only
a partially ablative conditioning regimen is used, then by defini-
tion susceptible T cell or myeloid cell targets will be available
posttransplant. In the absence of antiviral therapy, the virus
would be able to replicate, albeit in a more constrained manner.
Natural selection due to HIV-mediated death of susceptible cells
might be expected to result in a shift from a predominantly
HIV-susceptible CD4+ target population to a predominantly
HIV-resistant population. However, during this process, a virus
population that is resistant to the targeted gene function(s) could
emerge, resulting in failure of the therapy. Therefore, it will be
important to determine whether a period of antiviral suppression
during engraftment will be advantageous to stem cell
approaches and, if so, the optimal duration of therapy.
In Vivo Engraftment of Transduced HSCs
A recent publication by Holt et al. (2010) has demonstrated the
feasibility of targeting the CCR5 locus in NSG-repopulating cells.
The authors demonstrated successful engraftment of gene-
edited CD34+ cells in the NSG mouse model and subsequent
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frequency of disruption was 17%, with an estimated biallelic
modification of approximately 5%–7%. After irradiation with
150 cGy, nearly 40% of CD45 cells engrafted. The authors also
showed engraftment in secondary recipients with comparable
levels of gene-edited cells. Although these data are promising,
it is important to note that these animals received gene-modified
cells prior to HIV infection, which is obviously of limited relevance
to what might eventually occur in humans.
The rate at which HIV-resistant cells were selected in this
experiment was impressive: HIV infection in this model causes
rapid CD4+ T cell depletion and complete engraftment with
CCR5/ cells was evident by week 12. Given the pace of
disease progression in untreated HIV infection (on the order of
years rather than weeks), it is highly unlikely that such rapid
replacement will occur in humans, but a focused clinical trial
using this approach will be required to determine if this is the
case.
Pretransplant Conditioning Regimens
Although the animal studies described above clearly demon-
strate the feasibility and efficacy of transplanting HIV-resistant
HSCs, a major question remains: how can one achieve similar
engraftment in people infected with HIV? From large animal
studies, we know that HSC engraftment without conditioning is
likely to be very low, especially given the limited cell numbers
available for humans or large animals.
A variety of conditioning approaches have been studied in
nonhuman primate models, which allows for careful analysis of
the level of engraftment necessary to provide protection and
the most effective conditioning regimens for achieving this level.
Many conditioning regimens (e.g., the use of cyclophosphamide)
(Storb et al., 1970) were first tested in nonhuman primates, as
were the high-dose irradiation regimens now commonly used
for transplantation or stem cell gene therapy studies (Horn
et al., 2002; Trobridge et al., 2008). Other advantages of
nonhuman primate studies include the ability to carefully and
comprehensively analyze latent virus reservoirs by analyzing
peripheral blood apheresis products, GALT biopsies, and even
spinal fluid for the presence of integrated SIV or SHIV, as is
done for human patients, and the possibility of studying the
use of immunosuppressive agents, such as anti-thymocyte glob-
ulin, similar to those used in the case of the Berlin patient. Finally,
effective HAART treatment regimens are becoming better estab-
lished in monkeys, allowing the study of structured treatment
interruptions. Thus, while the NSG mouse model will facilitate
rapid and efficient evaluation of the function of gene-modified
or edited cells, nonhuman primate models will be important for
determining the conditions necessary to achieve sufficient
engraftment for long-term protection. Over the next several
years, it is hoped that effective and reasonably safe conditioning
regimens will be developed using nonhuman primate models.
If HSCs can be expanded ex vivo, alternative and better-toler-
ated conditioning regimens could be considered or conditioning
regimens might be avoided altogether. This has been nicely
demonstrated in mouse models, where higher doses of marrow
cells were able to successfully compete with endogenous HSCs
(Quesenberry et al., 1994; Stewart et al., 1993, 1998). An alterna-
tive strategy to optimize engraftment has been proposed byMazurier et al. (2003), who reported improved engraftment of
myeloerythroid cells when injected directly into the bonemarrow
as opposed to intravenously. A number of investigators have
since pursued this approach, and studies in nonhuman primates
also suggested a differential engraftment pattern (Jung et al.,
2007).
Progress has also been made in developing strategies to
select gene-modified cells in vivo. While this approach has
been shown to be highly effective when a chemoresistance
gene is being used in combination with chemotherapy (Beard
et al., 2010), other strategies that do not involve chemotherapy
are being developed and may provide a nontoxic selection
approach (Okazuka et al., 2011).
Design of HSC-Based Gene Therapy Clinical Trials
in Humans
Depending on the therapeutic approach, there are a number of
clinical development strategies that might be pursued. At least
in the near future, it is likely that all proof-of-principle studies to
explore how to ‘‘make space’’ for exogenous HSCs will be
carried out in patients with AIDS lymphoma or other diseases
requiring chemotherapy as a standard of care. Exceptions to
this rule might include transplantation of more mature lineage-
restricted gene-modified T cells and/or myeloid cells, an
approach that may not require as much, if any, preparative
conditioning. These studies, together with preclinical nonhuman
primate studies, will hopefully teach us more about the extent to
which engraftment of modified HSCs will facilitate the expansion
and protection of unmodified T and myeloid cells.
From an ethical perspective, another viable approach is to
perform transplants in patients for whom standard antiretroviral
drugs are not a viable option. Such patients might include those
with multidrug resistant HIV, although such patients are now rare
and most have very advanced disease; they may lack either
sufficient stem cells for transduction and/or the functional
lymphoid infrastructure necessary to support immune reconsti-
tution. A related group of patients includes those who choose
not take antiretroviral therapy or who have exhibited an inability
to adhere to any regimen, but even those patients are difficult to
define and are often not ideal clinical trial participants.
The ultimate patient population, however, is likely to be healthy
patients who are doing well on antiretroviral therapy and who
receive a transplant while remaining on therapy. In such cases,
several primary outcomes might be anticipated, including
a reduction in the size of the HIV reservoir, the absence of an
HIV rebound during treatment interruption, and/or reconstitution
of a more effective immune system.
Concluding Remarks
There is a growing international effort aimed at developing a cure
for HIV infection. A central dilemma in almost all cure strategies is
balancing the risks and benefits. Although the indefinite delivery
of antiretroviral therapy is not possible for many individuals,
those who do access and adhere to drugs generally have
a good prognosis. Because most cure strategies require that
complete or near complete inhibition of HIV replication be
achieved with therapy, the ideal patient population for testing
cure strategies will be one that is already on maximally suppres-
sive antiretroviral therapy. For gene therapy and stem cellCell Stem Cell 10, February 3, 2012 ª2012 Elsevier Inc. 143
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Reviewmodification protocols, early work has focused on treating
patients who require stem cell transplants for management of
a malignancy. Moving such studies into the general population
will require developing gene delivery approaches with a very
low risk of malignant transformation and transplant protocols
that require minimum conditioning regimens. Fortunately, there
are now integrating lentivirus and foamy virus vectors with signif-
icantly improved safety features, and nonintegrating vector
systems or simple transfection procedures are also available.
In addition, it is likely that the safety of gene delivery will continue
to improve and low-dose conditioning regimens have already
been used successfully in other gene therapy studies (Aiuti
et al., 2009). Given these advances, it is expected that it will at
least theoretically soon be possible to safely modify stem cells
ex vivo, to transplant cells without ablative conditioning into
healthy individuals on effective antiretroviral therapy (perhaps
by using large numbers of gene-modified cells or by using an
in vivo selection approach), and to then carefully interrupt
therapy, perhaps leading to selective advantage and expansion
of gene-modified cells. Finally, cost considerations will almost
certainly emerge as a dominant factor in weighing the practicality
of any curative strategy. Although gene modification of stem
cells will be an expensive intervention, it may prove to be cost-
effective given that decades-long administration of antiretroviral
therapy would cost several hundred thousand dollars per person
(Schackman et al., 2006). Thus, although there are many safety
and logistical barriers to be addressed, further pursuit of HSC-
based gene therapy may ultimately offer a curative strategy for
HIV disease.
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